DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

ChartTrends: Renal Anemia in Dialysis (US) 2013

In the United States, there are approximately 400,000 dialysis patients. Renal anemia is common in these patients. This annual report series covers the management of renal anemia in dialysis patients by reviewing patient charts. Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications, and a host of laboratory and patient demographic variables help define patient types and identify therapy triggers. In addition, the attitudinal survey component allows for a better understanding of the rationale for treatment decisions and gaps between intended and actual treatment.

Questions Answered in This Report:

  • Understand the demographics of dialysis patients
    -Underlying cause of renal failure, co-morbidities, vintage and common medications
    -Hospitalizations and cause of hospitalization
    -Vascular access type and interventions

  • Understand the standard of care for dialysis patients and changes over time
    -Use and frequency of laboratory assessments; laboratory values
    -Hemoglobin, TSAT, Ferritin
    -Albumin, Alkaline Phosphatase, Bicarbonate, Kt/v, URR, 25D, Total Cholesterol, LDL Cholesterol, Uric Acid, C-Reactive Protein, Calcium, Phosphorus, PTH
    -Quantify treatment prevalence of renal anemia medications (ESAs and iron)
    -Understand the interplay between the use of ESAs and Iron

  • Understand the selection process for renal anemia medications in dialysis
    -What factors drive brand selection (i.e. co-morbidities, concomitant therapies, lab value ranges, disease awareness attitudes, etc.)
    -Capture product dosing and titration
    -Capture switching behavior and reasons for switches
    -Characterize “Treated” versus “Non-Treated” patient groups

  • Identify characteristics that correlate with certain treatment approaches by comparing survey responses with actual treatment records


Sample Frame & Methodology:

- 200+ Nephrologists submit 1000+ Dialysis Patient Chart Records

Nephrologist Screening Criteria:

- In practice between 2 and 30 years

- Minimum of 50 adult dialysis patients under management

Patient Criteria:

- On dialysis for at least six months

- 18-89 years of age

- Currently on hemodialysis or peritoneal dialysis

All methods are HIPAA compliant

Product Coverage

- Epogen, Aranesp, Procrit, Venofer, Ferrlecit, Feraheme, INFeD, Dexferrum , Nulecit


- Final report in Powerpoint format

- Patient record database (in SPSS or Excel)

- Custom ad-hoc analysis available upon request with purchase of the report

- Access to analyst team for presentation or to address questions

Related Reports:

- TreatmentTrends®: US Nephrology

- TreatmentTrends®: Anemia Managers

- TreatmentTrends®: Renal Anemia (EU)

- ChartTrends®: Renal Anemia in CKD-ND

- ChartTrends: Renal Anemia (EU)

- CKD Pharmacor